N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington’s disease

Dean Wright, Laura J. Gray, David I. Finkelstein, Peter J. Crouch, David V. Pow, Terence Y. Pang, Shanshan Li, Zoe M. Smith, Paul S. Francis, Thibault Renoir,

Human Molecular Genetics · 2016 · 62 citations · 42 references

DOIFull text

Open access

Concepts

Abstract

and GLT-1 inhibitors CPG and DHK, showing that glutamate transporter activity was required for the antidepressant effects of NAC. NAC was also able to specifically increase glutamate in HD mice, in a glutamate transporter-dependent manner. These in vivo changes reflect changes in glutamate transporter protein in HD mice and human HD post-mortem tissue. Furthermore, NAC was able to rescue changes in key glutamate receptor proteins related to excitotoxicity in HD, including NMDAR2B. Thus, we have shown that baseline reductions in cysteine underlie glutamatergic dysfunction and depressive-like behavior in HD and these changes can be rescued by treatment with NAC. These findings have implications for the development of new therapeutic approaches for depressive disorders.

References

42